Form 4: ARTELO BIOSCIENCES CEO and CFO Granted Significant Stock Options

ARTELO BIOSCIENCES, INC. disclosed that its President, CEO, CFO, and Treasurer, Gregory D. Gorgas, was granted 40,393 stock options with an exercise price of $11.03, subject to multi-year vesting schedules.

Summary

• Gregory D. Gorgas, President, CEO, CFO, Treasurer, and Director of ARTELO BIOSCIENCES, INC. (ARTL), was granted stock options.
• The grants occurred on July 2, 2025.
• A grant of 20,393 stock options was made with an exercise price of $11.03 and an expiration date of July 2, 2035.
• These 20,393 options vest monthly at 1/48th of the shares, starting from January 1, 2025, and fully vesting on the four-year anniversary of that date.
• An additional grant of 20,000 stock options was made with an exercise price of $11.03 and an expiration date of July 2, 2035.
• These 20,000 options vest in two tranches: 50% on January 1, 2026, and the remaining 50% on January 1, 2027.
• The total number of stock options granted to Mr. Gorgas is 40,393.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of stock options to a key executive is a standard practice for aligning incentives, but it does not inherently signal strong positive or negative news about the company's immediate performance. The future value depends entirely on stock price appreciation.

Positives

• Granting of stock options to a key executive like the CEO/CFO aligns management's interests with shareholder value creation, as the options become valuable if the stock price rises above the exercise price.
• The multi-year vesting schedules encourage long-term commitment and retention of a critical executive.

Negatives

• The exercise price of $11.03 is the current market price at the time of grant, meaning the options only have value if the stock price increases from this level.
• Potential for future dilution for existing shareholders if these options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is contingent on the future performance of ARTELO BIOSCIENCES, INC.'s stock price. If the stock price does not exceed the exercise price of $11.03, the options may expire worthless.
• The vesting schedules require the reporting person to continue as a 'Service Provider' to the company, indicating a risk of forfeiture if employment ceases before full vesting.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if the options incentivize the CEO to drive stock price appreciation.
• Employees: The mention of the Issuer's 2018 Equity Incentive Plan suggests a broader framework for employee compensation, potentially impacting morale and retention across the company.

Next Steps

• Continued vesting of stock options for Gregory D. Gorgas based on the specified schedules.
• Potential exercise of stock options by Gregory D. Gorgas if the stock price exceeds the exercise price of $11.03.

Key Dates

Keywords

ARTELO BIOSCIENCES, ARTL, Stock Options, Equity Compensation, Insider Trading, SEC Form 4, Executive Compensation, Gregory D. Gorgas, Vesting Schedule, Biotechnology, Pharmaceuticals